These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15124695)

  • 1. P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults.
    Kolitz JE; George SL; Baer MR; Lee EJ; Bloomfield CD; Larson RA;
    Ann Hematol; 2004; 83 Suppl 1():S103-4. PubMed ID: 15124695
    [No Abstract]   [Full Text] [Related]  

  • 2. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
    Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
    J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
    Kolitz JE; George SL; Dodge RK; Hurd DD; Powell BL; Allen SL; Velez-Garcia E; Moore JO; Shea TC; Hoke E; Caligiuri MA; Vardiman JW; Bloomfield CD; Larson RA;
    J Clin Oncol; 2004 Nov; 22(21):4290-301. PubMed ID: 15514371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Results of clinical trials in the treatment of acute myeloid leukemia in adults during a 7-year period].
    Savchenko VG; Parovichnikova EN; Kliasova GA; Isaev VG; Pivnik AV; Khoroshko ND; Ol'shanskaia IuV; Tikhonova LIu; Maslova ER; Kulikov SM
    Ter Arkh; 1999; 71(7):13-20. PubMed ID: 10481861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
    Marcucci G; Mrózek K; Ruppert AS; Maharry K; Kolitz JE; Moore JO; Mayer RJ; Pettenati MJ; Powell BL; Edwards CG; Sterling LJ; Vardiman JW; Schiffer CA; Carroll AJ; Larson RA; Bloomfield CD
    J Clin Oncol; 2005 Aug; 23(24):5705-17. PubMed ID: 16110030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction chemotherapy for acute myelogenous leukemia.
    Kalaycio M
    Curr Hematol Rep; 2005 Jan; 4(1):49-50. PubMed ID: 15610659
    [No Abstract]   [Full Text] [Related]  

  • 8. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
    van der Holt B; Van den Heuvel-Eibrink MM; Van Schaik RH; van der Heiden IP; Wiemer EA; Vossebeld PJ; Löwenberg B; Sonneveld P
    Clin Pharmacol Ther; 2006 Nov; 80(5):427-39. PubMed ID: 17112800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420.
    Lee EJ; George SL; Caligiuri M; Szatrowski TP; Powell BL; Lemke S; Dodge RK; Smith R; Baer M; Schiffer CA
    J Clin Oncol; 1999 Sep; 17(9):2831-9. PubMed ID: 10561359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive post-remission therapy with Ara-C in adults with acute myeloid leukemia: initial results of a CALGB phase III trial. The Cancer and Leukemia Group B.
    Mayer RJ; Davis RB; Schiffer CA; Berg DT; Sarno E; Frei E
    Leukemia; 1992; 6 Suppl 2():66-7. PubMed ID: 1578945
    [No Abstract]   [Full Text] [Related]  

  • 12. [The results of a multicenter cooperative study on treating acute myeloid leukemias in adults].
    Savchenko VG; Parovichnikova EN; Kliasova GA; Isaev VG; Kulikov SM; Tikhonova LIu; Cherepanova VV; Rekhtman GB; Medvedeva NV; Kaporskaia TS
    Ter Arkh; 1994; 66(7):11-7. PubMed ID: 7985120
    [No Abstract]   [Full Text] [Related]  

  • 13. [The current chemotherapy of acute myeloid leukemias in adults].
    Poddubnaia IV; Perilov AA
    Ter Arkh; 1993; 65(7):86-9. PubMed ID: 8211791
    [No Abstract]   [Full Text] [Related]  

  • 14. [The results of 2 and 1/2 years of work of the Russian Multicenter Trial on the Treatment of Acute Myeloid Leukemias in Adults].
    Savchenko VG; Parovichnikova EN; Gliasova GA; Isaev VG; Kulikov SM; Tikhonova LIu; Cherepanova VV; Rekhtman GB; Medvedeva NV; Kaporskaia TS
    Ter Arkh; 1995; 67(7):8-12. PubMed ID: 7482315
    [No Abstract]   [Full Text] [Related]  

  • 15. Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
    Harousseau JL; Milpied N; Briere J; Desablens B; Leprise PY; Ifrah N; Gandhour B; Casassus P
    Semin Hematol; 1991 Jul; 28(3 Suppl 4):80-3. PubMed ID: 1780758
    [No Abstract]   [Full Text] [Related]  

  • 16. Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
    Matsouka P; Pagoni M; Zikos P; Giannakoulas N; Apostolidis I; Asprogeraka T; Arvanitopoulou E; Spanoudakis E; Kotsianidis I; Tsatalas K; Papaioannou M; Marinakis T; Skandali A; Viniou N; Yataganas X; Bakiri M
    Ann Hematol; 2006 Apr; 85(4):250-6. PubMed ID: 16416114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.
    Xu WL; Shen HL; Ao ZF; Chen BA; Xia W; Gao F; Zhang YN
    Leuk Res; 2006 Apr; 30(4):407-13. PubMed ID: 16219352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia.
    Saini L; Minden MD; Schuh AC; Yee KW; Schimmer AD; Gupta V; Atenafu EG; Murray C; Nixon S; Brandwein JM
    Am J Hematol; 2012 Mar; 87(3):323-6. PubMed ID: 22213349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating childhood acute myeloid leukaemia with the AML-BFM-83 protocol: experience in a developing country.
    Chan LL; Abdel-Latif ME; Ariffin WA; Ariffin H; Lin HP
    Br J Haematol; 2004 Sep; 126(6):799-805. PubMed ID: 15352983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
    Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.